Abstract： Objective： To observe the clinical effect of governor vessel application with Rivastigmine Transdermal Patch on mild- to- moderate Alzheimers disease (AD). Methods： A total of 90 patients with mild- to- moderate AD were divided into the governor vessel application group， the routine application group and the Donepezil Hydrochloride group according to the random number table method，with 30 cases in each group. The Donepezil Hydrochloride group was given Donepezil Hydrochloride Tablets，the routine application group was given routine application with Rivastigmine Transdermal Patch， and the governor vessel application group was given governor vessel application with Rivastigmine Transdermal Patch. Before and after treatment， the scores of Alzheimers Disease Assessment Scale- Cognitive Subscale (ADASCog)， Mini- Mental State Examination (MMSE)， Alzheimers Disease Assessment Scale- Clinical Global Impression of Change (ADAS- CGIC) and Alzheimers Disease Assessment Scale- Activities of Daily Living (ADAS- ADL) were compared among the three groups， and the incidence of adverse reactions in the three groups was recorded. Results：After 12 and 24 weeks of treatment，the scores of ADAS-CGIC and ADAS- Cog in the three groups were decreased when compared with those before treatment (P＜0.05)， the scores of MMSE and ADAS- ADL were increased when compared with those before treatment (P＜ 0.05)，and the scores of ADAS-CGIC and ADAS-Cog in the governor vessel application group were lower than those in the routine application group and the Donepezil Hydrochloride group，respectively (P＜0.05)， the scores of MMSE and ADAS-ADL were higher those in the routine application group and the Donepezil Hydrochloride group ， respectively (P ＜ 0.05). After 24 weeks of treatment，the scores of ADAS- CGIC and ADAS-Cog in the routine application group were lower than those in the Donepezil Hydrochloride group (P＜0.05)， the scores of MMSE and ADAS- ADL were higher than those in the Donepezil Hydrochloride group (P＜0.05). The incidence of adverse reactions in the governor vessel application group and the routine application group was lower than that in the Donepezil Hydrochloride group， respectively (P＜0.05). Conclusion：The therapy of governor vessel application with Rivastigmine Transdermal Patch for mild-tomoderate AD can effectively improve the cognitive function， self- care ability and clinical symptoms of patients with good safety.